BioNTech vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?

Investors choosing between BioNTech (NASDAQ:BNTX) and Vertex Pharmaceuticals (NASDAQ:VRTX) must weigh the massive potential of mRNA cancer research against the reliable, high-margin cash flows of a dominant cystic fibrosis treatment leader.

BioNTech is famous for its role in COVID-19 vaccines but is now pivoting toward oncology. Vertex Pharmaceuticals dominates the cystic fibrosis market while expanding into new areas like gene therapy. Both companies represent different stages of the biotechnology lifecycle, making them popular comparisons for healthcare investors seeking long-term growth.

The case for BioNTech

BioNTech focuses on developing immunotherapies and mRNA-based medicines for cancer and infectious diseases. In its latest annual report, filed for the period ending December 31, 2025, the company noted it employed roughly 8,052 people. While it gained global fame for its vaccine success, the business strategy now centers on commercializing oncology treatments in the United States and other major global markets.

In FY 2025, revenue reached nearly $3.2 billion, representing growth of approximately 4.3% compared to the previous year. Despite this growth, the company reported a net loss of approximately $1.3 billion for the period. This resulted in a net margin of negative 39.6%, which measures the percentage of revenue remaining after all expenses are accounted for.

As of its December 2025 balance sheet, the company maintained a debt-to-equity ratio of 0.0x, indicating it carries no debt. The current ratio was approximately 7.5x, which measures a company's ability to cover its short-term liabilities with assets. Free cash flow for the year was close to $299.4 million, which is the cash a company generates after accounting for capital expenditures.

The case for Vertex Pharmaceuticals

Vertex Pharmaceuticals is a global leader focused on treating serious diseases, specifically through its dominant cystic fibrosis franchise. The company sells its medicines primarily to a limited number of specialty pharmacy and specialty distributors, and this customer concentration adds a layer of risk to the business. To diversify its reach, it maintains research agreements with CRISPR Therapeutics (NASDAQ:CRSP), Moderna (NASDAQ:MRNA), Entrada Therapeutics (NASDAQ:TRDA), and Zai Lab (NASDAQ:ZLAB).

In FY 2025, revenue reached approximately $12 billion, a growth rate of around 9% over the prior year. The company reported a net income of close to $4.0 billion, which indicates significant profitability compared to many other biotech stocks. This performance resulted in a healthy net margin of approximately 32.7%.

As of its December 2025 balance sheet, the debt-to-equity ratio was roughly 0.1x. This metric measures total debt relative to shareholder equity, suggesting the company uses very little borrowed money to fund its operations. The current ratio was approximately 2.9x, and the company generated close to $3.2 billion in free cash flow, representing the cash left over after paying for capital assets.

Risk profile comparison

BioNTech faces significant risks as it transitions its business model toward oncology after the decline of pandemic-related vaccine demand. The success of its future growth depends heavily on the clinical trial results of its mRNA pipeline, which is both expensive and unpredictable. Any failure to demonstrate safety or efficacy in these new therapies could harm the valuation and long-term prospects of the business.

Vertex Pharmaceuticals is heavily reliant on its cystic fibrosis franchise, as substantially all net product revenues come from this single treatment area. The company also faces clinical development risks, evidenced by recent setbacks for VX-264 and regulatory challenges regarding label expansions for other candidates. Additionally, global healthcare systems are increasing focus on cost containment, which may pressure future pricing and reimbursement for its therapies.

Valuation comparison

Vertex Pharmaceuticals currently reports positive earnings and established sales, while BioNTech is navigating a transition period as it shifts its focus from vaccines to cancer therapies.

Valuation metrics include sourcing from Financial Modeling Prep (FMP) and may differ from other data providers.

Which stock would I buy for 2027?

I'd go with Vertex Pharmaceuticals. It already brings in billions from its cystic fibrosis medicines, and that business is still growing: Revenue rose 12% in Q3 and the company raised its full-year outlook. It is also the dominant name in that market, which has given it steady profits for years.

In its Q3 2026 results reported on Nov. 2, Vertex's growth came from its newest cystic fibrosis medicine, Alyftrek, and from newer treatments for sickle cell disease and pain. Its reported profit fell because of costs from buying Crinetics, but that deal adds a rare hormone-disease business, and an FDA decision on a kidney drug is due Nov. 30.

To give BioNTech its due, it has a huge cash pile and a growing pipeline of cancer treatments. But its Q3 revenue fell as COVID vaccine sales faded. What's more, its research spending is climbing while those treatments are still being tested.

Building long-term wealth means owning a business that already makes money while it builds the next one. Vertex does that, using cystic fibrosis profits to fund new medicines, which is why it is my pick.

Sara Appino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends BioNTech Se, Moderna, and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.